Cobra Biologics Ltd.. (1/23/18). "Press Release: Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK". Keele.

	Region	United Kingdom (GB)
	Organisation	Cobra Biologics Ltd.
	Group	Cobra Biologics (Group)
	Organisation 2	United Kingdom (GB) (govt)
	Product	contract manufacturing (biologicals)
	Product 2	business development (state/region)
	Person	Coleman, Peter (Cobra Biologics 201106 CEO– before RecipharmCobra Biologics)
	Person 2	Fairhead, Rona (United Kingdom (govt) 201801 Minister of State for Trade and Exports)

> Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK

> Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments

Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, announced that it has been awarded £2.6 million ($3.4 million) capital infrastructure investment by Innovate UK. The award has been made under Innovate UK’s Industrial Strategy boost for UK medicines with £70 million of funding to help develop new treatments. The investment will go towards a £5 million development project, which forms part of a wider £15 million company expansion announced by Cobra in 2017, to advance world leading capabilities for clinical and commercial production of viral vectors and DNA, vital for gene therapy and immune-oncology programmes.

The extended capacity and capability will allow Cobra increased process development, analytics and GMP manufacturing, and importantly provides the necessary infrastructure to offer commercial in-market supply of viral vector and DNA products to Advanced Therapy Medicinal Product (ATMP) developers. The expansion will double the footprint of Cobra’s UK site and create 25-35 additional jobs.

Peter Coleman, Chief Executive of Cobra Biologics, commented: “Cobra is undertaking a very significant expansion of our viral and DNA manufacturing capability and we are very pleased to have received funding from Innovate UK to help accelerate our plans. The investment recognises Cobra as a leading company in the cell and gene therapy market and provides us, and the UK, with a unique opportunity to be at the forefront of developing revolutionary disease therapies and new treatments for patients.”

Minister of State for Trade and Exports, Baroness Rona Fairhead said: “The UK is a world leader in the Life Sciences industry, and our advanced gene therapies offer the potential to improve dramatically the lives of millions.

“The expansion of Cobra is an exciting development. It will create further highly skilled jobs and allow Cobra to drive their exports, while demonstrating UK leadership in another industry of the future.”

ENDS

Notes to Editors:

Peter Coleman, CEO Cobra Biologics
For a high resolution images please contact sarah.jeffery@zymecommunications.com

Contacts

Media enquiries

Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0)7771 730919

At Cobra Biologics

Peter Coleman
Chief Executive Officer
E-mail: peter.coleman@cobrabio.com
Phone: +44 (0)1782 714181

About Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

For more information please visit: www.cobrabio.com

About Innovate UK

Innovate UK is the UK's innovation agency. It drives productivity and growth by supporting businesses to realise the potential of new technologies, develop ideas and make them a commercial success.

With a strong business focus, Innovate UK drives growth by working with companies to de-risk, enable and support innovation.

For further information visit: www.innovateuk.org

https://www.gov.uk/government/news/improved-healthcare-for-all-pioneering-projects-get-funding

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/672702/Viral_Vector_Manufacturing_for_Cell_and_Gene_Therapies_-_Challenge_Fund_-_Competition_Results.pdf

https://www.gov.uk/government/news/industrial-strategy-boost-for-uk-medicines-with-70-million-of-funding-to-help-develop-new-treatments

Record changed: 2018-02-01

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Cobra Biologics Ltd.. (1/23/18). "Press Release: Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK". Keele.

More documents for Cobra Biologics (Group)